Delix Therapeutics Announces Positive Efficacy Data for DLX-001 (Zalsupindole) and FDA Clearance of Phase II Trial Design Featuring At‑Home Administration

Nature biotechnology editor’s pick: Constructive Bio

Constructive Bio joins Ellison Institute to find new medicines

VedaBio Announces Strategic Agreement with Siemens Healthineers and Series A Extension, Totaling Up to $25 Million

VedaBio Accelerating Amplification-Free Syndromic POC MDx With Additional CRISPR IP

VedaBio Expands CRISPR-Based Molecular Detection Platform With Mammoth Biosciences’ Technology

The Microbiome May Hold the Key to IVF Success

Matterworks Inc. Secures Series A Funding to Advance to Advance Machine Intelligence for Predictive Biology

Manus and Inscripta merge to create a leader in industrial biomanufacturing

Freya: Restoring microbial balance in the reproductive tract

VedaBio Appoints Rachel Jones as Chief Commercial Officer

Delix Presents Full Results from Phase 1 Trial of DLX-001 at ACNP Annual Meeting